The Cost of GLP-1 Drugs on Payers’ Minds as Nearly 1/3rd of U.S. Consumers Could Become Users
Health Populi
AUGUST 6, 2024
With 70 different clinical trials for GLP-1 drugs in process with the FDA, payers — and other stakeholders in the health care ecosystem — have the semaglutide-SENSE top of mind, based on my ongoing updating of this fast-moving market space. For overall market context on pace-of-growth in adoption, check out this chart from a JAMA Health Forum research letter on Prescription Fills for Semaglutide Products by Payment Method , published August 2nd.
Let's personalize your content